Member Info for Bella6532

Grrrr phone...FTI consulting.

Oh and RedX also use FDI Consulting...

Thanks Myles.
LG Chem is looking good if you read their Patent.

There are many patents out there which mention the use of affimer(s) directly or as an option. IMO it certainly won't be long before we see more trials and/or products coming to market.

AS will be presenting to a bunch of investors on 30th and so will RedX in the same session.
They are looking at targeted cancer treatments and are very much a direct competitor of ours.

Having been faced with a similar situation personally at the point of launching our new Distributorship in the US we met up with a couple of guys who were known to us and in the process of doing exactly the same in exactly the same marketplace but with different key principals..so we approached them and merged before we launched..the synergy was amazing...
Would a RedX/Avacta merger be totally out of the question do you think?

PAH00
Perhaps the Mologic buy out changed things...maybe Medusa have decided they want to produce the whole thing now...or it's simply as a new assembler with new machinery it's just taking time to get everything working correctly and consistently...not as simple as one might think...
Equipment/materials supply, installation and staffing issues due Covid/Brexit/Transportation etc etc etc...could all be a factor.
Agree something has caused the delay and morelikely at Medusa end...

Tweaked...grrr

EGTP '- so the only question remaining - what is the demand for such a product over the next 5 to 10 years ?'
Actually I would add to that...and what other pathogens will they target.

Once Avacta gets all its ducks in a row for its LFT, the strip can easily be tweeted to detect other serious pathogens around the globe...its not going to be just one LFT to detect Covid...they will roll out new versions as time goes on...

Cra601...they should be accounting for and including all income receipts and payable debts up to and including 30 June 2021.

Don't forget AS will be speaking at this at 1345 and a bunch of investors will be attending...so what will our results contain that he will be able to also crow about to said investors...
https://bionow.co.uk/event/BIONOW099/2021-biocap-conference

Would AVA6000 fit into their product/target market goals???
https://innovation.lgchem.com/ResearchDevelopment/OurScience.do

The answers could be right in front of our noses....ever heard of a 'man's look'...lol!!!

Doze...may I suggest you get your questions in...
Have you seen how big LG Chem is and we are already partnered with them...they could have said they'll take it if it works...
FTI Consulting was bought in for a reason...they've kept us shut down...they should be getting info out to the Financial media...they're either lazy or know the importance of NDAs/Confidentiality Agreements. Yes it's frustrating and they are the doormen and direct access/communications with Avacta by shareholders is no longer possible...
Why?????

Again for those who don't quite get timescales in this business...this was back in 2019...the Clinical Trial has just got underway and a good set of results will have a real impact on how highly toxic chemo is administered globally...but it will still take time...this is long haul tech...LFTs will be the short cashflow generator...
https://avacta.com/tmac-programme-accelerates-clinical-trial-planned-early-2020/

Also worth reiterating this statement too..
'If a similar reduction in cardiotoxicity is seen in humans in the phase I clinical trial of AVA6000, then there is the potential for a major license deal that could generate a transformational, non-dilutive, upfront payment of tens of millions of dollars. This funding would support all Avacta’s other programmes in future. The pre|CISIONTM technology to improve the safety of a large number of other established chemotherapies and generate similar licensing opportunities. For this reason, the Company is prioritising this programme.'

What dies he mean by 'There is the potential for a major licence'...is that just wishful thinking or is there someone in the wings just waiting for the results...if this works we'll sign the dotted line sort of deal...

Richob...'There is no doubt that the Medusa owners know how to sell and I can't see why they would invest £20m in a commercial venture if they weren't looking for a substantial return on it.'

Add to that the fact we believe they are still shareholders in Avacta....you think they like seeing the SP where it is right now too...

'But if you mention facts, you get called a deramper.'...
Facts are facts and so far I don't see anything which could lead to deramping.
We are where we are SP wise because that's the way the markets work not because of anything Avacta have or have not done.

Some nice trades yesterday..was the SP dropped to fill...?

20-Sep-21 10:19:10 26.90 25,000 Buy* 6,725 O
20-Sep-21 10:17:20 26.50 10,000 Unknown* 2,650 O
20-Sep-21 10:16:22 27.30 100,000 Buy* 27.30k O
20-Sep-21 10:11:14 26.70 25,000 Buy* 6,675 O
20-Sep-21 10:10:27 26.70 25,000 Buy* 6,675 O
20-Sep-21 09:00:16 27.50 350,000 Buy* 96.25k O

Are the trying to get HUA for both tests? If so thus might be a reason for length of time it's taking.

I know the Medusa boys are well heeled but I don't think even they would consider spending £20m just to sit on their hands and wait around for a few pen pushers to sign off on their product(s)...I'm sure they and Avacta will be doing everything possible to get things setup and moved along...

Blame the pen pushers not Avacta...

gmcc...thanks for your input too...
Afraid developing new products from new affimer tech isn't going to happen over night. Avacta have managed to get affimers into the research labs of some great companies who are themselves beavering away to develop their own new products. For those invested here looking for a quick fix, it just isn't going to happen unless we can get our LFT out there in volume for both pro & home use. I think Avacta have actually played it well by taking on the challenge of developing and launching an LTF to not only be used for Covid and it's various mutations but also it's highly and quickly adaptable to be used for other pathogens too. With Calibre already selling and Medusa coming soon this will generate a nice steady income stream. They didn't have develop and LFT, they could have just spent their time and energy developing affimers for new partners/licencees to follow through with.
Todays nonsense is a great sign something is going on in the trading rooms...the 5k, 10k,15k and 20k trades were so obvious today and the bunch of green on my screen tells me they've been out in force trying to scare poor old PI's who don't know better into selling either so they or their minders can buy low and then 'poof' they'll be gone and the SP will rise and those same shares are sold off for a profit or tucked safely into an II's closet.

Will there be news this week...who knows...maybe or maybe not.
Next week...yes, for sure.

A bit more information for you all...
The neonatal crystallizable fragment receptor (FcRn) functions as an intracellular protection receptor for immunoglobulin G (IgG). Recently, several clinical studies have reported the lowering of circulating monomeric IgG levels through FcRn blockade for the potential treatment of autoimmune diseases.

Published 22/4/2021
Title
'(EN) NEONATAL FC RECEPTOR BINDING AFFIMERS
Provided herein, in some embodiments, are AFFIMER® polypeptides that binds to the neonatal Fc receptor (FcRn) and extends the half-life of the polypeptides. Also provided herein, in some embodiments, are compositions containing the polypeptides, methods of using the polypeptides, and methods of producing the polypeptides.'
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021075930&tab=PCTBIBLIO&_cid=P11-KTSVMY-95496-1

Oh they do like to use the word affimer don't they....just scroll down in link below to see full text:

Solution to Problem
[7]
An object of the present invention is to provide a polypeptide comprising an FcRn binding AFFIMER® sequence that binds to human FcRn.
[8]
Another object of the present invention is to provide a pharmaceutical preparations.
[9]
Another object of the present invention is to provide a methods that comprise administering to a subject having an autoimmune disease and/or an inflammatory disease.
[10]
Another object of the present invention is to provide a provide methods of increasing serum half-life of a therapeutic molecule.
[11]
Another object of the present invention is to provide a use of the polynucleotide for targeting FcRn.
[12]
A further object of the present invention is to provide a use of the polynucleotide for increasing serum half-life of a therapeutic molecule.
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021075930&tab=FULLTEXT&_cid=P11-KTSVMY-95496-1

Told you it was all going on behind closed doors...look and you will find...

Orphidian...do we know if the Medusa boys are still Avacta shareholders? The original Distributor deal with Medusa was a profit share deal, can we assume that deal still stands unchanged apart from it no longer being a saliva test. If so, would it be in the boys interest to allow Avacta to put out an RNS re HUA as they are receiving a profit share which could be financially meaningful for Avacta and for the boys as shareholders.

Also a little word of caution re the results. They are only interims and any revenue streams from indirect sales by our partners/licencees will often be paid on a delayed basis...something like quarterly or 30 days following the date of invoice etc. If there has been an increase in income since the end of June, I really hope AS takes it upon himself to at least give us an indication of this in a forward looking statement...anticipated percentage growth in income for 2nd half would be good. And for those who say this can't be done, well others do it so why can't we...even just saying income will be heavily weighted in the 2nd half of the year. Can but hope eh!!!